Literature DB >> 8494838

Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome.

I Wada1, P L Matson, S A Troup, B A Lieberman.   

Abstract

OBJECTIVE: To compare the outcome of in vitro fertilisation (IVF) and gamete intrafallopian transfer (GIFT) cycles in women with or without ultrasound features of polycystic ovary syndrome (PCOS).
DESIGN: A consecutive series from January to December 1989.
SUBJECTS: Twenty-five women with PCOS scheduled for assisted conception. The controls were 139 women with normal ovaries.
SETTING: A single centre specialist fertility unit, Manchester, UK.
INTERVENTIONS: Pituitary desensitisation was with buserelin. In the PCOS group ovarian stimulation was with 1 ampoule (75 iu FSH) of hMG/day in 12 women (Group I) and two ampoules/day in 13 (Group II). The controls (Group III) were given two ampoules of hMG daily. Human chorionic gonadotrophin (hCG; 10,000 iu) was given when three follicles measured > or = 20 mm diameter. MAIN OUTCOME MEASURES: Serum oestradiol (E2) concentrations, number of follicles, clinical pregnancies, features of the ovarian hyperstimulation syndrome (OHS).
RESULTS: Women with PCOS (Groups I or II) had more follicles > or = 14 mm diameter on the day of the hCG injection (P < 0.005), higher serum E2 concentrations on the day after the hCG (P < 0.05) and more oocytes retrieved (P < 0.05) than the controls. The OHS was more prevalent in those with PCOS (32% versus 6.5%; P < 0.05). The clinical pregnancy rate per embryo transfer (27% versus 22%) or gamete transfer (25% versus 39%) and the rate of spontaneous miscarriage (33% versus 12%) were not statistically different.
CONCLUSIONS: The pregnancy rate and outcome of pregnancy following IVF or GIFT in women with or without PCOS are similar. Women with PCOS are at a higher risk of developing OHS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494838     DOI: 10.1111/j.1471-0528.1993.tb12981.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

Authors:  Ali Abbara; Channa N Jayasena; Georgios Christopoulos; Shakunthala Narayanaswamy; Chioma Izzi-Engbeaya; Gurjinder M K Nijher; Alexander N Comninos; Deborah Peters; Adam Buckley; Risheka Ratnasabapathy; Julia K Prague; Rehan Salim; Stuart A Lavery; Stephen R Bloom; Matyas Szigeti; Deborah A Ashby; Geoffrey H Trew; Waljit S Dhillo
Journal:  J Clin Endocrinol Metab       Date:  2015-07-20       Impact factor: 5.958

3.  A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.

Authors:  Ali Abbara; Sophie Clarke; Rumana Islam; Julia K Prague; Alexander N Comninos; Shakunthala Narayanaswamy; Deborah Papadopoulou; Rachel Roberts; Chioma Izzi-Engbeaya; Risheka Ratnasabapathy; Alexander Nesbitt; Sunitha Vimalesvaran; Rehan Salim; Stuart A Lavery; Stephen R Bloom; Les Huson; Geoffrey H Trew; Waljit S Dhillo
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

4.  Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.

Authors:  A Abbara; R Islam; S A Clarke; L Jeffers; G Christopoulos; A N Comninos; R Salim; S A Lavery; T N L Vuong; P Humaidan; T W Kelsey; G H Trew; W S Dhillo
Journal:  Clin Endocrinol (Oxf)       Date:  2018-03-06       Impact factor: 3.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.